2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBrazilCost-Benefit AnalysisFemaleHumansMaleMarkov ChainsMass ScreeningMiddle AgedMycobacterium tuberculosisPrisonersRifampinTuberculosisYoung AdultConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthPotential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium tuberculosisRifampinTreatment OutcomeTuberculosisTuberculosis, Multidrug-ResistantConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalenceThe recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova
Chitwood M, Colijn C, Yang C, Crudu V, Ciobanu N, Codreanu A, Kim J, Rancu I, Rhee K, Cohen T, Sobkowiak B. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova. Nature Communications 2024, 15: 2962. PMID: 38580642, PMCID: PMC10997638, DOI: 10.1038/s41467-024-47282-9.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug Resistance, Multiple, BacterialGenotypeHumansMoldovaMycobacterium tuberculosisTuberculosis, Multidrug-ResistantConceptsMDR M. tuberculosisGenome sequenceResistance-conferring mutationsBeijing sublineageMDR strainsReproductive fitnessBeijing strainsCulture-positive casesLineagesMtb strainsMultidrug-resistant tuberculosisMDRMtbStrainMDR-TBMutationsResistant tuberculosisMDR-MTBSubstantial riskSublineagesTuberculosisSequenceIdentifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model
Lan Y, Crudu V, Ciobanu N, Codreanu A, Chitwood M, Sobkowiak B, Warren J, Cohen T. Identifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model. EBioMedicine 2024, 102: 105085. PMID: 38531172, PMCID: PMC10987885, DOI: 10.1016/j.ebiom.2024.105085.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremDrug Resistance, Multiple, BacterialGenotypeHumansLogistic ModelsMoldovaMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantConceptsPatterns of spatial aggregationMtb strainsMDR-TBLogistic regression modelsGenome Epidemiology StudySpecific strainsMultidrug-resistant tuberculosisTreated TB casesNational Institute of AllergyMDR phenotypeRegression modelsM. tuberculosisInstitute of AllergyMultinomial logistic regression modelUS National Institutes of HealthNational Institutes of HealthMDR diseasePublic health concernAssociated with local transmissionIncident TBInstitutes of HealthMtbResistant tuberculosisStrainDiagnosing TB
2023
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis
Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, Utpatel C, Cirillo D, Rodrigues C, Nilgiriwala K, Fowler P, Merker M, Niemann S, Consortium C, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Dreyer V, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grandjean L, Grazian C, Groenheit R, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Khot R, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Mansjö M, Matias D, Meintjes G, de Freitas Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Musser K, Ngcamu D, Hoang N, Niemann S, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Rodger G, Rodrigues C, Rodwell T, Roohi E, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker S, Warren R, Werngren J, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Yu X, Yang Y, Zhao Y, Yao S, Zhu B. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. The Lancet Microbe 2023, 4: e358-e368. PMID: 37003285, PMCID: PMC10156607, DOI: 10.1016/s2666-5247(23)00002-2.Peer-Reviewed Original ResearchConceptsMutation catalogueIn silico data analysisBedaquiline resistanceClofazimine resistanceResistance mechanismsProtein modelsClinical Mycobacterium tuberculosis complex isolatesImpaired DNA bindingClinically resistant strainsMinimum inhibitory concentrationVariants in vitroPacBio sequencingGenome sequenceGenomic rearrangementsGenomic variantsIn vitroExperimental evolutionGenotype dataTranscriptional repressorDrug resistance mechanismsClinical isolatesPhenotypic dataResistance determinantsDNA bindingProtein dimerisationSpatial Modeling of Mycobacterium Tuberculosis Transmission with Dyadic Genetic Relatedness Data
Warren J, Chitwood M, Sobkowiak B, Colijn C, Cohen T. Spatial Modeling of Mycobacterium Tuberculosis Transmission with Dyadic Genetic Relatedness Data. Biometrics 2023, 79: 3650-3663. PMID: 36745619, PMCID: PMC10404301, DOI: 10.1111/biom.13836.Peer-Reviewed Original ResearchEstimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States
Ekramnia M, Li Y, Haddad M, Marks S, Kammerer J, Swartwood N, Cohen T, Miller J, Horsburgh C, Salomon J, Menzies N. Estimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States. Epidemiology 2023, 35: 164-173. PMID: 38290139, PMCID: PMC10832387, DOI: 10.1097/ede.0000000000001707.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes MellitusHIV InfectionsHumansKidney Failure, ChronicMycobacterium tuberculosisNutrition SurveysTuberculosisUnited StatesConceptsInterferon-gamma release assayNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyUS-born statusNational TB Surveillance SystemReactivation TBNutrition Examination SurveyInterferon-gammaIGRA sensitivityTB surveillance systemProgression to tuberculosis diseaseNationally representative dataEnd-stage renal diseaseReactivation rateAmerican Community SurveyExamination SurveyPerson yearsRace-ethnicityUS populationTB ratesTB incidenceCommunity SurveyRepresentative dataSurveillance systemRelease assay
2022
Quantifying Mycobacterium tuberculosis Transmission Dynamics Across Global Settings: A Systematic Analysis
Smith J, Cohen T, Dowdy D, Shrestha S, Gandhi NR, Hill AN. Quantifying Mycobacterium tuberculosis Transmission Dynamics Across Global Settings: A Systematic Analysis. American Journal Of Epidemiology 2022, 192: 133-145. PMID: 36227246, PMCID: PMC10144641, DOI: 10.1093/aje/kwac181.Peer-Reviewed Original ResearchMeSH KeywordsHumansMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantWhole Genome SequencingConceptsTB transmissionOngoing TB transmissionMinority of casesTuberculosis transmission dynamicsTB controlTuberculosis transmissionSecondary casesSources of heterogeneityInclusion criteriaSurveillance studyTransmission clustersInitial searchTransmission dynamicsWhole-genome sequencingPopulation levelSettingBudget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchMeSH KeywordsDrug ResistanceHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsMoldovaMycobacterium tuberculosisTuberculosis, Multidrug-ResistantConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volumeNeighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi
Khundi M, Carpenter JR, Corbett EL, Feasey HRA, Soko RN, Nliwasa M, Twabi H, Chiume L, Burke RM, Horton KC, Dodd PJ, Cohen T, MacPherson P. Neighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi. PLOS ONE 2022, 17: e0268749. PMID: 35605004, PMCID: PMC9126376, DOI: 10.1371/journal.pone.0268749.Peer-Reviewed Original ResearchMeSH KeywordsAdultBayes TheoremHumansMalawiMass ScreeningMycobacterium tuberculosisPrevalenceSputumTuberculosisConceptsCase notification ratesPrevalence surveyNotification ratioNeighbourhood prevalenceTB case notification ratesXpert MTB/RIFCase-finding interventionsTrue disease burdenChest X-ray screeningTB prevalence surveyTB surveillance systemMTB/RIFDiagnosis of tuberculosisSputum smear microscopyTB clinicTB patientsRespiratory infectionsTB prevalenceDisease burdenNotification ratesSmear microscopyX-ray screeningTuberculosisPrevalenceUrban tuberculosisA crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
Fowler P, Wright C, Spiers H, Zhu T, Baeten E, Hoosdally S, Cruz A, Roohi A, Kouchaki S, Walker T, Peto T, Miller G, Lintott C, Clifton D, Crook D, Walker A, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grazian C, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Matias D, Meintjes G, Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Dreyer V, Chetty D, Musser K, Ngcamu D, Nhung H, Grandjean L, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Robinson E, Rodger G, Rodrigues C, Rodwell T, Roohi A, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Steyn A, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker A, Warren R, Werngren J, Groenheit R, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Xiao Y, Yang Y, Yanlin Z, Yao S, Zhu B, Niemann S, O'Donnell M. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates. ELife 2022, 11: e75046. PMID: 35588296, PMCID: PMC9286738, DOI: 10.7554/elife.75046.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHumansMicrobial Sensitivity TestsMycobacterium tuberculosisTuberculosisVolunteersConceptsMinimum inhibitory concentrationIncreasing prevalence of resistanceBroth microdilution platesAntibiotic susceptibility testingPrevalence of resistanceInhibitory concentrationPanel of antibioticsClinical samplesSusceptibility testingMicrodilution platesDilution platingTreatment outcomesIncreased prevalenceAntitubercular drugsAntibioticsInhibited growthDrugCitizen science platformRespiratory diseaseLaboratory scientistsVolunteersPre-determined concentrationsThe 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Walker T, Miotto P, Köser C, Fowler P, Knaggs J, Iqbal Z, Hunt M, Chindelevitch L, Farhat M, Cirillo D, Comas I, Posey J, Omar S, Peto T, Suresh A, Uplekar S, Laurent S, Colman R, Nathanson C, Zignol M, Walker A, Crook D, Ismail N, Rodwell T, Consortium T, Walker A, Steyn A, Lalvani A, Baulard A, Christoffels A, Mendoza-Ticona A, Trovato A, Skrahina A, Lachapelle A, Brankin A, Piatek A, Cruz A, Koch A, Cabibbe A, Spitaleri A, Brandao A, Chaiprasert A, Suresh A, Barbova A, Van Rie A, Ghodousi A, Bainomugisa A, Mandal A, Roohi A, Javid B, Zhu B, Letcher B, Rodrigues C, Nimmo C, NATHANSON C, Duncan C, Coulter C, Utpatel C, Liu C, Grazian C, Kong C, Köser C, Wilson D, Cirillo D, Matias D, Jorgensen D, Zimenkov D, Chetty D, Moore D, Clifton D, Crook D, van Soolingen D, Liu D, Kohlerschmidt D, Barreira D, Ngcamu D, Lazaro E, Kelly E, Borroni E, Roycroft E, Andre E, Böttger E, Robinson E, Menardo F, Mendes F, Jamieson F, Coll F, Gao G, Kasule G, Rossolini G, Rodger G, Smith E, Meintjes G, Thwaites G, Hoffmann H, Albert H, Cox H, Laurenson I, Comas I, Arandjelovic I, Barilar I, Robledo J, Millard J, Johnston J, Posey J, Andrews J, Knaggs J, Gardy J, Guthrie J, Taylor J, Werngren J, Metcalfe J, Coronel J, Shea J, Carter J, Pinhata J, Kus J, Todt K, Holt K, Nilgiriwala K, Ghisi K, Malone K, Faksri K, Musser K, Joseph L, Rigouts L, Chindelevitch L, Jarrett L, Grandjean L, Ferrazoli L, Rodrigues M, Farhat M, Schito M, Fitzgibbon M, Loembé M, Wijkander M, Ballif M, Rabodoarivelo M, Mihalic M, WILCOX M, Hunt M, ZIGNOL M, Merker M, Egger M, O'Donnell M, Caws M, Wu M, Whitfield M, Inouye M, Mansjö M, Thi M, Joloba M, Kamal S, Okozi N, ISMAIL N, Mistry N, Hoang N, Rakotosamimanana N, Paton N, Rancoita P, Miotto P, Lapierre P, Hall P, Tang P, Claxton P, Wintringer P, Keller P, Thai P, Fowler P, Supply P, Srilohasin P, Suriyaphol P, Rathod P, Kambli P, Groenheit R, Colman R, Ong R, Warren R, Wilkinson R, Diel R, Oliveira R, Khot R, Jou R, Tahseen S, Laurent S, Gharbia S, Kouchaki S, Shah S, Plesnik S, Earle S, Dunstan S, Hoosdally S, Mitarai S, Gagneux S, Omar S, Yao S, Lapierre S, Battaglia S, Niemann S, Pandey S, Uplekar S, Halse T, Cohen T, Cortes T, Prammananan T, Kohl T, Thuong N, Teo T, Peto T, Rodwell T, William T, Walker T, Rogers T, Surve U, Mathys V, Furió V, Cook V, Vijay S, Escuyer V, Dreyer V, Sintchenko V, Saphonn V, Solano W, Lin W, van Gemert W, He W, Yang Y, Zhao Y, Qin Y, Xiao Y, Hasan Z, Iqbal Z, Puyen Z. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. The Lancet Microbe 2022, 3: e265-e273. PMID: 35373160, PMCID: PMC7612554, DOI: 10.1016/s2666-5247(21)00301-3.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug ResistanceEthambutolMicrobial Sensitivity TestsMutationMycobacterium tuberculosisWorld Health OrganizationConceptsConsistent with susceptibilityAssociated with resistancePhenotypic resistanceDrug susceptibility testingSusceptibility testingPositive predictive valueAssociated with phenotypic resistanceWhole-genome sequencingPrevalence of phenotypic resistanceMolecular diagnosticsDrug susceptibility testing dataUniversal drug susceptibility testingMutations associated with drug resistanceOdds ratioSusceptibility testing dataDrug resistance predictionImplementation of molecular diagnosticsBinary phenotypesPredictive valueGene approachMTBC isolatesUnique mutationsFisher's exact testAnti-tuberculosis drugsGenotype analysisPhylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
Yang C, Sobkowiak B, Naidu V, Codreanu A, Ciobanu N, Gunasekera KS, Chitwood MH, Alexandru S, Bivol S, Russi M, Havumaki J, Cudahy P, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Menzies NA, Warren JL, Crudu V, Colijn C, Cohen T. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLOS Medicine 2022, 19: e1003933. PMID: 35192619, PMCID: PMC8903246, DOI: 10.1371/journal.pmed.1003933.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisDrug-resistant M. tuberculosisM. tuberculosis strainsPutative transmission clustersM. tuberculosisTransmission clustersMultidrug-resistant M. tuberculosis strainsTuberculosis strainsMultiple M. tuberculosis strainsCulture-positive TB casesLocal transmissionMDR-TB epidemicDrug-susceptible tuberculosisDrug resistance mutationsDrug resistance profilesUrgency of interventionTB casesDemographic dataNew casesTuberculosisInadequate treatmentNatural historyResistance mutationsBeijing lineageMycobacterium tuberculosis
2021
A Cluster-based Method to Quantify Individual Heterogeneity in Tuberculosis Transmission
Smith JP, Gandhi NR, Silk BJ, Cohen T, Lopman B, Raz K, Winglee K, Kammerer S, Benkeser D, Kramer MR, Hill AN. A Cluster-based Method to Quantify Individual Heterogeneity in Tuberculosis Transmission. Epidemiology 2021, 33: 217-227. PMID: 34907974, PMCID: PMC8886690, DOI: 10.1097/ede.0000000000001452.Peer-Reviewed Original ResearchEvolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova
Brown TS, Eldholm V, Brynildsrud O, Osnes M, Levy N, Stimson J, Colijn C, Alexandru S, Noroc E, Ciobanu N, Crudu V, Cohen T, Mathema B. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova. Microbial Genomics 2021, 7: 000620. PMID: 34431762, PMCID: PMC8549355, DOI: 10.1099/mgen.0.000620.Peer-Reviewed Original ResearchConceptsDrug-resistant TB casesMultidrug-resistant Mycobacterium tuberculosisDrug-resistant tuberculosisDrug resistance mutationsPopulation size expansionPublic health practiceSoviet UnionSocial turmoilTB patientsTB casesTB controlRepublic of MoldovaInpatient hospitalizationMigration historyInpatient treatmentEastern EuropeNational guidelinesEpidemiological historyResistance mutationsHealth practicesGenomic surveillance effortsCapital cityMycobacterium tuberculosisTuberculosisMoldovaThe impact of COVID-19 on TB: a review of the data
McQuaid C, Vassall A, Cohen T, Fiekert K, COVID/TB Modelling Working Group *, White R. The impact of COVID-19 on TB: a review of the data. The International Journal Of Tuberculosis And Lung Disease 2021, 25: 436-446. PMID: 34049605, PMCID: PMC8171247, DOI: 10.5588/ijtld.21.0148.Peer-Reviewed Original ResearchLaboratory costs of diagnosing TB in a high multidrug-resistant TB setting
Cates L, Crudu V, Codreanu A, Ciobanu N, Fosburgh H, Cohen T, Menzies N. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting. The International Journal Of Tuberculosis And Lung Disease 2021, 25: 228-230. PMID: 33688812, PMCID: PMC7948759, DOI: 10.5588/ijtld.20.0586.Peer-Reviewed Original ResearchAntitubercular AgentsCosts and Cost AnalysisHumansLaboratoriesMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDevelopment of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis
Gunasekera KS, Walters E, van der Zalm MM, Palmer M, Warren JL, Hesseling AC, Cohen T, Seddon JA. Development of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis. Clinical Infectious Diseases 2021, 73: e904-e912. PMID: 33449999, PMCID: PMC8366829, DOI: 10.1093/cid/ciab018.Peer-Reviewed Original ResearchConceptsPulmonary tuberculosisClinical evidenceXpert MTB/RIFBaseline clinical evaluationChest radiographic resultsRapid treatment initiationNational Tuberculosis ProgrammeTreatment decision algorithmsEvidence-based algorithmMTB/RIFDiagnosis of tuberculosisChest radiographicAntituberculosis treatmentProspective cohortRadiographic resultsTreatment initiationTuberculosis casesTuberculosis ProgrammeClinical evaluationCase definitionTreatment decisionsGlobal burdenChildhood mortalityChildren EvaluatedRapid clinical diagnosis
2020
Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completionTime Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States
Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon JA. Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2020, 32: 70-78. PMID: 33009253, PMCID: PMC7707158, DOI: 10.1097/ede.0000000000001271.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansIncidenceLatent TuberculosisMycobacterium tuberculosisProbabilityRiskTuberculosisUnited StatesConceptsLatent TB infectionMycobacterium tuberculosis infectionTB infectionTuberculosis infectionTB natural historyRisk of tuberculosisMost TB casesRate of progressionYounger age groupsLower future riskTransmission dynamic modelTB casesTB riskPrevalent infectionProgression riskLifetime riskRisk factorsIncidence trendsClinical diseaseCumulative riskGeneral populationAverage ageNew infectionsUS populationAge groups